Biotech

All Articles

Actinogen's cortisol blocker stops working period 2 clinical depression study

.Actinogen Medical's cortisol blocker has missed out on the major endpoint of a period 2 research st...

Bivictrix chooses going private only means to take ADC in to clinic

.Antibody-drug conjugates (ADCs) have actually been at the facility of many a billion-dollar biobuck...

TPG tops up funds to $580M for financial investments across lifestyle sciences

.Possession manager TPG, which has assisted biotechs like Sionna Therapies as well as Santa Ana Biog...

Merck quits phase 3 TIGIT trial in lung cancer for impossibility

.Merck &amp Co.'s TIGIT course has actually gone through one more problem. Months after shuttering a...

After a hard year, Exscientia folds up in to Recursion

.After a year described through pipeline cuts, the variation of its own chief executive officer and ...

Cullinan, after $25M package, restore bispecific to Harbour

.Cullinan Rehab was wowed good enough with Harbour BioMed's bispecific immune activator that it surr...

A closer take a look at Fierce Biotech's Ferocious 15

.Within this full week's episode of "The Best Line," our team're diving in to Strong Biotech's annua...

Lilly deals with period 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's gathering commemorating the commenda...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of substantial management hirings, firings an...

Lykos will talk to FDA to reconsider its own decision observing rejection of MDMA therapy for post-traumatic stress disorder

.Adhering to a poor presenting for Lykos Rehabs' MDMA candidate for trauma at a current FDA advisory...